Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)

16 novembre 2026 aggiornato da: Istituto Ortopedico Rizzoli

Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)

The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:

  • How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
  • Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.

During a single clinic visit, participants will:

  • Have standard x-rays of their hands and wrists
  • Have a routine ultrasound of their hands and wrists
  • Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.

High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.

To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.

At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).

Tipo di studio

Interventistico

Iscrizione (Stimato)

140

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Bologna
      • Bologna, Bologna, Italia, 40136
        • IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
    • Verona
      • Verona, Verona, Italia, 37134
        • Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Rheumatoid Arthritis (RA) Cohort:

  • Age ≥ 60 years
  • Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
  • Clinical diagnosis confirmed by an expert rheumatologist
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Calcium Pyrophosphate Deposition (CPPD) Cohort:

  • Age ≥ 60 years
  • Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Control Cohort (Non-inflammatory Controls):

  • Age ≥ 60 years
  • Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
  • Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
  • Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
  • Written informed consent obtained

Exclusion Criteria:

All Cohorts:

  • Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
  • Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
  • Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
  • Inability to provide written informed consent

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Rheumatoid Arthritis (RA) Cohort

Patients with RA and current or prior hand/wrist involvement (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Altri nomi:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparatore attivo: Healthy / Non-inflammatory Controls

Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Altri nomi:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparatore attivo: CPPD Positive Control Cohort

Patients with proven CPPD disease (n = 20).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Altri nomi:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Lasso di tempo: Baseline (single imaging visit)

Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.

Baseline (single imaging visit)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of HR-pQCT-positive cases missed by conventional imaging
Lasso di tempo: Baseline (single imaging visit)

Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.

Baseline (single imaging visit)
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Lasso di tempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Lasso di tempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Lasso di tempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.

Baseline (single imaging visit)
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Lasso di tempo: Baseline (single imaging visit)

Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.

Baseline (single imaging visit)
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Lasso di tempo: Baseline (single imaging visit)

Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.

Baseline (single imaging visit)
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Lasso di tempo: Baseline (single imaging visit)

Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.

Baseline (single imaging visit)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Lasso di tempo: Baseline (single imaging visit)

Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.

Baseline (single imaging visit)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

30 aprile 2029

Completamento dello studio (Stimato)

31 ottobre 2029

Date di iscrizione allo studio

Primo inviato

6 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HAND-QCT-RA

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .